Related Experiment Video
Updated: Dec 1, 2025

07:48
Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
9.1K
GRK2 Dictates a Functional Switch of the Peripheral Mu-Opioid Receptor
ACS Chemical Neuroscience
|November 11, 2020
Summary
Peripheral mu-opioid receptor (MOR) activity is regulated by G protein-coupled receptor kinase 2 (GRK2). Uncoupling GRK2 from MOR in sensory neurons can restore pain relief, offering potential for safer analgesia.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Peripheral mu-opioid receptors (MOR) are targets for safer analgesia.
- Limited understanding of peripheral MOR signaling mechanisms.
- GRK2's role in regulating MOR activity was previously unknown.
Purpose of the Study:
- Investigate the signaling mechanisms controlling peripheral MOR activity.
- Identify key regulators of MOR functional states in sensory neurons.
- Explore therapeutic potential for modulating peripheral MOR signaling.
Main Methods:
- Studied interactions between GRK2 and MOR in peripheral sensory neurons.
- Utilized bradykinin (BK) to modulate receptor activity.
- Employed RNA interference to silence RKIP.
- Assessed MOR functionality in dorsal root ganglion (DRG) neurons.
- Investigated the effect of paroxetine on GRK2-MOR uncoupling.
Main Results:
- GRK2 constitutively interacts with MOR, suppressing its activity in peripheral sensory neurons.
- Brief BK exposure uncouples GRK2 from MOR, restoring functionality.
- Prolonged BK treatment leads to constitutive MOR activation via PKC.
- Silencing RKIP abrogates BK-induced constitutive MOR activation.
- Constitutive peripheral MOR activity requires GRK2 uncoupling.
- Paroxetine promotes GRK2-MOR uncoupling.
Conclusions:
- GRK2 is a key regulator of peripheral MOR functional states.
- Modulating GRK2-MOR interaction offers a strategy for safer analgesia.
- Targeting GRK2 may provide novel therapeutic approaches for pain management.
Related Concept Videos
Opioid Receptors: Overview
3.3K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
3.3K
GPCR Desensitization
7.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.4K
Analgesia and Pain Management
1.2K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.2K
GPCRs Regulate Adenylyl Cylase Activity
6.5K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.5K
The Two-State Receptor Model
2.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.9K
Cholinergic Receptors: Muscarinic
4.3K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
4.3K

